Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06292741
Recruiting Not applicable

Autonomic Involvement in Patient With Cognitive Decline

NCT06292741 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Not applicable
Started
2023-01-11
Last updated
2026-09-02

Condition(s) studied

Dementia, MildDementia of Alzheimer Type

Investigational drug(s) / intervention(s)

Sudoscan

Sudoscan: recording of sudomotor function and pupillary reactivity

Study summary

Prospective interventional study with a device for comparing autonomic parameters among patients with different forms of cognitive decline

Eligibility

Sex
ALL
Min age
50 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * male and females between 50 and 85 years * cognitive decline (dementia, lewy's body dementia, Parkinson dementia, Alzheimer dementia) * mild cognitive decline ( lewy's body MCI, Parkinson MCI and Alzheimer MCI) * Ability to assume the upright position Exclusion Criteria: * diabetes mellitus * eye problems * severe cognitive decline * heart disease * peripheral neuropathy * language barrier * oncological disease * medical pathologies associated with cognitive deficits

Primary outcome measure(s)

  • evaluation of the prevalence in autonomic dysfunction in patients with MCI and dementia — baseline through study completion, an average of 3 year
    evaluation of the prevalence in autonomic dysfunction in patients with MCI and dementia

Trial sites (1)

FacilityCityRegionStatus
Clinica della memria- Fondazione Policlinico Agostino Gemelli IRCCS Rome Lazio Recruiting

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

The Management of Asymptomatic Carotid Stenosis Recruiting
Modular Neurological Examination for Early Risk Detection Active, not recruiting
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. Recruiting
BRCA Mutation Carriers' Platform a Multicenter Study Recruiting
Superior Cervical Ganglion in Parkinson's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06292741 on ClinicalTrials.gov ↗ ← All trials in Italy